BioCentury | Jul 5, 2010
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Years cash pre-cut Cash date 1Q10 operating loss 4/7/10 TopoTarget A/S (CSE:TOPO) 17% to 40 $51.9 NA 3/31/10 Profitable Cuts are from research and preclinical development; expects annual...
BioCentury | Jul 5, 2010
Finance

2Q approvals

2Q approvals Company Approvals Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Japan approves Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH) Amgen Inc. (NASDAQ:AMGN) FDA approves Prolia denosumab to treat osteoporosis in postmenopausal women whoare at high risk...
BC Week In Review | May 17, 2010
Company News

Avexa infectious news

Avexa plans to reduce headcount and pursue strategic alternatives after discontinuing development of HIV candidate apricitabine. Avexa said it was unable to find a partner for the cytidine analog nucleoside reverse transcriptase inhibitor (NRTI), which...
BioCentury | May 17, 2010
Finance

Regulatory Milestones

Amgen Inc. (NASDAQ:AMGN) could move on Monday this week after the company announced late last Friday that it had submitted a BLA to FDA for denosumab to reduce skeletal related events (SREs) in cancer patients....
BC Extra | May 12, 2010
Company News

Avexa discontinues apricitabine

Avexa Ltd. (ASX:AVX) plans to reduce headcount and pursue strategic alternatives after discontinuing development of HIV candidate apricitabine. Avexa said it was unable to find a partner for the cytidine analog nucleoside reverse transcriptase inhibitor...
BC Week In Review | Jun 8, 2009
Clinical News

Apricitabine: Phase III ongoing

An independent DSMB recommended continuation of Avexa's international Phase III trial evaluating apricitabine at the 800 mg dose based on 16-week data from 3 treatment arms comparing 800 or 1,200 mg of oral apricitabine given...
BC Extra | May 1, 2009
Financial News

Avexa raises A$17 million

Avexa Ltd. (ASX:AVX) raised A$17 million (US$12.2 million) in a rights issue of 242.9 million shares at A$0.07. The price is a 22% discount to Avexa's close of A$0.09 on April 3, the record date...
BioCentury | Mar 30, 2009
Finance

2Q09 milestones

2Q09 milestones Company Product Indication Milestone Milestone date Advanced Life (NASDAQ:ADLS) Cethromycin Community-acquired pneumonia (CAP) FDA panel 6/2/09 AGI Therapeutics (ISE:A9I; LSE:AGI) Rezular arverapamil (AGI-003) Diarrhea-predominant irritable bowel syndrome (IBS-D) Prelim Ph III data 2Q09...
BC Week In Review | Mar 23, 2009
Clinical News

Apricitabine: Additional Phase IIb data

An open-label extension of the 48-week Phase IIb AVX-201 trial in 51 patients showed that about 87% of 39 patients receiving 800 mg apricitabine twice daily with other HIV medications as needed had undetectable plasma...
BC Week In Review | Feb 2, 2009
Company News

Avexa, Cytopia, Progen deal

Cytopia and a group of other Progen shareholders are seeking to replace Progen's board with a slate of three independent directors, merge the two companies and offer a buyback of 100% of Progen shares at...
Items per page:
1 - 10 of 33